What is SES-CD? The Simple Endoscopic Score for Crohn’s disease (SES-CD), sometimes referred to in full as a simplified endoscopic activity score for Crohn’s disease, is a structured way to quantify mucosal inflammation and structural complications seen at ileocolonoscopy. It was developed to capture the endoscopic burden of Crohn’s disease (CD) using a small number of clearly defined items that endoscopists can score quickly while still correlating strongly with the older, more labor-intensive Crohn’s Disease Endoscopic Index of Severity (CDEIS).

SES-CD is widely used in clinical research, registry work, and quality improvement when teams want a reproducible numeric summary of mucosal disease. In everyday care, the score can help document baseline severity, communicate findings across multidisciplinary teams, and track change after therapy—provided the examination quality, extent, and lesion definitions are handled consistently.

Why use an endoscopic score in Crohn’s disease?

Crohn’s disease is patchy and transmural. Symptoms, biomarkers, and imaging do not always mirror what the mucosa looks like during endoscopy. Endoscopic scoring attempts to standardize what is seen: ulcer size, how much surface is ulcerated, how much bowel is affected by any CD-type lesion, and whether luminal narrowing is present. SES-CD focuses on features that have been considered both clinically relevant and reasonably reproducible among trained observers when definitions are followed carefully.

Unlike purely narrative endoscopy reports, a numeric index supports aggregation across patients and time points. That is especially important for “treat-to-target” discussions about mucosal healing, where trials and guidelines increasingly emphasize objective disease activity measures. SES-CD is not a stand-alone substitute for clinical judgment; it complements history, physical examination, laboratory studies, histology, cross-sectional imaging, and patient priorities.

Anatomy of the score: five ileocolonic segments

SES-CD is calculated separately within each of five segments, then summed:

• Ileum
• Right colon
• Transverse colon
• Left colon
• Rectum

In each segment, four endoscopic domains are scored from 0 to 3. The segment subtotal therefore ranges from 0 to 12. Summing all five segments yields a global SES-CD from 0 to 60, with higher values reflecting more extensive or severe mucosal disease and more impactful stricturing in the examined segments.

The four endoscopic variables (0–3 each, per segment)

The four domains are intended to be scored using the visible mucosa in that segment during a well-prepared examination. Practical details matter: lesion size is often assessed relative to familiar endoscopic landmarks (for example, the approximate width of biopsy forceps jaws), and surface area judgments require mentally integrating the proportion of the visible segment that is involved.

1) Size of ulcers

This item emphasizes the largest relevant ulcer morphology in the segment rather than simply counting every aphthous spot. Typical scoring anchors are:

• 0: no ulceration
• 1: small (“aphthous”) ulcers, classically around 0.1–0.5 cm
• 2: larger ulcers, classically around 0.5–2 cm
• 3: very large ulcers, classically greater than about 2 cm

When multiple ulcer sizes coexist, scoring usually follows the worst/most representative category according to the protocol used locally or in a trial. Very small erosions versus frank ulceration can be a gray zone; teams reduce disagreement by agreeing ahead of time how shallow lesions are categorized in their documentation system.

2) Ulcerated surface (extent of ulceration among visible mucosa)

This item estimates how much of the examined surface in that segment is ulcerated, expressed in broad ordinal bands:

• 0: none
• 1: less than about 10% of visible mucosa
• 2: about 10–30%
• 3: greater than about 30%

This variable drives sensitivity to “ulcer load,” which is a frequent therapeutic target because ulcers are an intuitive marker of active mucosal injury. It also interacts with the next item: a patient can have limited ulceration but more widespread inflammatory change, or conversely confluent ulceration affecting a high fraction of the surface.

3) Affected surface (extent of disease among visible mucosa)

Here “affected” refers to the proportion of visible mucosa involved by Crohn’s disease lesions more broadly, not only ulcers. That can include erythema, loss of vascular pattern, edema, nodularity, and other inflammatory changes, depending on how the team operationalizes the definition.

• 0: none
• 1: less than about 50% of visible mucosa
• 2: about 50–75%
• 3: greater than about 75%

This domain helps SES-CD reflect disease burden even when ulceration is absent or limited, which matters in milder phenotypes or in healing trajectories where inflammation persists after ulcers improve.

4) Narrowing / stenosis

Crohn’s disease can narrow the lumen due to inflammation, fibrosis, or both. SES-CD grades whether strictures are absent, present but traversable, multiply traversable, or not passable with the endoscope. A commonly used anchor scheme is:

• 0: none
• 1: a single narrowing that the endoscope can pass
• 2: multiple narrowings that remain passable
• 3: cannot be passed

Stricturing disease can limit complete inspection; when the endoscope cannot traverse a lesion, downstream mucosa may be unseen and the clinical interpretation must explicitly acknowledge incomplete assessment.

How the total SES-CD is formed

For each segment, add the four domain scores. Repeat for all five segments and add the segment subtotals. A commonly reported mental check is:

• Per segment maximum: 3 + 3 + 3 + 3 = 12
• Global maximum: 12 × 5 = 60

Some publications also discuss relationships between SES-CD and CDEIS for research purposes; teams performing both indices should follow the exact source protocol rather than mixing variable definitions across instruments.

Interpreting totals: severity bands and “healing” endpoints

SES-CD is a continuous measure; cutoffs for inactive disease, response, and remission have varied across studies. A frequently reproduced pragmatic stratification groups severity as:

• Inactive / quiescent: total score roughly 0–2 in many analyses
• Mild: roughly 3–6
• Moderate: roughly 7–15
• Severe: roughly >16

Endoscopic remission and mucosal healing are not defined uniformly. Some trials emphasize an SES-CD of 0 as the strictest mucosal endpoint, while others use 0–2 or 0–3 depending on the research question and adjudication plan. Response is also defined in multiple ways, including percent reduction from baseline or crossing from a higher severity band to a lower one.

Because thresholds are partly empirical, the safest clinical approach is to align documentation and decision-making with the guideline or study definition in use, and to avoid over-interpreting small differences around a single numeric boundary without clinical context.

Practical pitfalls that change SES-CD validity

• Bowel preparation and visualization: poor prep obscures lesions and can falsely lower scores.
• Incomplete examination: stopping at a stricture or patient intolerance leaves segments unscored or inferred; many research protocols specify how to handle unscored segments.
• Ileal disease nuances: ileal involvement may be clinically meaningful even when global SES-CD appears modest; complementary imaging may be needed for transmural complications.
• Interobserver variability: agreement improves with training, central reading in trials, and consistent photographic documentation.
• Concurrent conditions: infection, ischemic change, NSAID injury, and post-surgical anatomy can mimic or mask CD activity.

How this calculator fits into clinical education

This tool is intended to help learners apply SES-CD arithmetic consistently and to visualize per-segment contributions to the global score. It does not replace the endoscopic examination, structured reporting, histopathology correlation, or specialist management. Patients and clinicians should interpret SES-CD alongside symptoms, objective inflammation markers, growth and nutrition (when relevant), and individualized treatment goals.